James Ohr

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT

Marie‐Nicole Theodoraki, Saigopalakrishna S. Yerneni, William E. Gooding et al. · OncoImmunology · 2019 · 164 citations · Full text

A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck

John A. Vargo, Robert L. Ferris, James Ohr et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 147 citations

Radiation Medicine, Radiation Therapy, Medicine +7

A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma

Weijing Sun, Anuj Patel, Daniel P. Normolle et al. · Cancer · 2018 · 121 citations

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Athanassios Argiris, Shuli Li, P. Savvides et al. · Journal of Clinical Oncology · 2019 · 117 citations · Full text